Pipeline file · from the 250-topic plan

Retatrutide, tracked honestly: the 24% molecule you cannot buy — and shouldn't try to

What the third receptor adds

Tirzepatide's bet was that GIP-plus-GLP-1 beats GLP-1 alone; the head-to-head vindicated it. Retatrutide raises: add glucagon receptor agonism — counterintuitive (glucagon raises blood sugar) but metabolically potent, increasing energy expenditure and liver fat burning while the incretin pair suppresses intake. Eat less and burn more is the theoretical jackpot; the phase-2 curve suggests the theory cashes.

The phase-2 data, with its honest edges

In the NEJM-published phase 2: ~24.2% average loss at 48 weeks on the top dose — with the curve still descending at trial's end, implying the 72-week number would run higher. Liver-fat substudies showed dramatic reductions. The edges: a few hundred participants (phase-2 scale), notable heart-rate increases requiring phase-3 characterization, and the class GI profile at least intact. Extraordinary signal, appropriately unfinished — which is precisely what phase 3 (the TRIUMPH program) exists to finish.

Where approval actually stands

Phase-3 trials are underway across obesity and related indications; no approval application has completed; no launch date exists that isn't speculation. The realistic horizon, if the data holds, is measured in years-not-months from this writing — and this page's dateline governs its shelf life: pipeline facts age fast, and we'd rather you re-check than quote us stale.

The gray market, named plainly

Because retatrutide is unapproved, no legal consumer channel exists: 503A pharmacies compound copies of approved drugs, and there is nothing approved to copy. Every "retatrutide" sold today — peptide sites, gym-adjacent Telegrams, "research use only" vials — is untested synthesis with no identity, purity, sterility or dose verification, sold with a label that legally means not for humans and functionally means no one checked. This isn't the compounded-versus-brand trade-off, where a licensed pharmacy and a real prescription anchor the floor; it's the floor removed. Our position needs one sentence: a molecule's trial average is not transferable to a vial nobody regulated.

The waiting-game math

"Should I wait for retatrutide?" prices out badly. Waiting years costs years of the ~15–21% treatments already approved — compounding health costs, not just scale ones (the diabetes-prevention extension alone reframes delay). Switching later is routine (the switch guide exists for exactly this), so starting now forfeits nothing except the gray market's risks. Today's rational stack: today's molecules at honest prices — the audited flats run $1,428–$1,668 — with tomorrow's molecule earning its file the way the last two did: in public, in trials, on this page when it's real. Today's audited options ↗

FAQ

How much weight loss did retatrutide show?

About 24.2% average at 48 weeks in phase 2 — with the curve still falling at trial's end — the largest pharmacotherapy result printed, pending phase-3 confirmation.

Can I buy retatrutide or get it compounded?

No legal channel exists: it's unapproved, and compounding requires an approved drug to copy. Everything sold as retatrutide today is unregulated gray-market synthesis.

Should I wait for retatrutide instead of starting tirzepatide?

The math says no: waiting costs years of proven 15–21% treatment for an unfixed date, and switching later is routine. Start with today's evidence; upgrade when tomorrow's is real.

What are retatrutide's known concerns?

Phase-2 flagged heart-rate increases needing characterization, plus the class GI profile — exactly what the ongoing phase-3 program is sized to resolve.

Sources

• Jastreboff AM, et al. Retatrutide phase-2 obesity trial, NEJM 2023; liver-fat substudy publications.
• TRIUMPH phase-3 program registrations and status.
• FDA compounding framework (503A) — why unapproved molecules have no compounding pathway.
• FDA and state-board warnings on "research use only" peptide sales.